This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Endocyte Announces Presentations At AACR Annual Meeting 2013

WEST LAFAYETTE, Ind., April 3, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that four poster presentations will be presented by Endocyte scientists at the 2013 Annual Meeting of the American Association for Cancer Research (AACR) to be held in Washington, D.C., April 6-10, 2013.

"Significant advances were made to our SDMC technology platform over the past year which collectively have led to the discovery of several new lead molecules that are currently in preclinical development," said Christopher Leamon, Ph.D., vice president of research and development. "We are excited to take part in this year's AACR meeting where we will discuss the applications of our pipeline compounds for cancer therapy."

Presentations are as follows:

Abstract #: 2145
Title: "PSMA-specific anti-tumor activity of the targeted-tubulysin conjugate, EC1169"
When:  Monday, April 8, 1 p.m. – 5 p.m. EDT 
Session ID:   Novel Targeted Therapies 1
Location:    Hall A-C, Poster Section 40
   
Abstract #: 4499
Title: "Total synthesis of tubulysins: A new chemical reaction leads to analogues with enhanced cytotoxicity" 
When:  Tuesday, April 9, 1 p.m. – 5 p.m. EDT
Session ID:  Genome and Microtubule Integrity
Location:  Hall A-C, Poster Section 42
   
Abstract #: 5623
Title: "Extracellular thiols and system x c play a significant role in non-targeted in vitro activity of a folate-tubulysin B conjugate"
When:  Wednesday, April 10, 8 a.m. – noon EDT
Session ID:   Novel Delivery Technologies
Location:   Hall A-C, Poster Section 41
   
Abstract #: 5502
Title: "Vintafolide: a first-in-class small molecule drug conjugate targeting folate receptor positive tumors"
When:  Wednesday, April 10, 8 a.m. – noon EDT
Session ID:   Chemotherapy and Cancer Dependencies
Location:   Hall A-C, Poster Section 37

About Endocyte

Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,051.12 +71.99 0.42%
S&P 500 1,989.78 +3.27 0.16%
NASDAQ 4,522.9120 -3.57 -0.08%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs